Trial Profile
An Open-label, Multicenter, Phase 1/1b Dose Escalation Study Evaluating the Pharmacokinetics, Safety, Tolerability, and Preliminary Efficacy of DCDS0780A, Alone or in Combination With Rituximab, or Obinutuzumab, in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jan 2022
Price :
$35
*
At a glance
- Drugs DCDS 0780A (Primary) ; Obinutuzumab; Rituximab
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Roche
- 03 Jan 2022 Results published in the Clinical Cancer Research
- 27 Aug 2019 Status changed from active, no longer recruiting to completed.
- 12 Dec 2017 Results (n=48; As of May 31, 2017) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology